MGCD290: Phase I data

In a double-blind, placebo-controlled, Canadian Phase I trial (Study 290-004) in 16 healthy volunteers, 270 and 540 mg/day oral MGCD290 plus 400 mg fluconazole for 14 days was well tolerated with no c...